Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
March 20, 2024
Date of Report (Date of earliest event reported)
Chimerix, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-35867 33-0903395
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
2505 Meridian Parkway, Suite 100
Durham, NC
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (919) 806-1074

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareCMRXThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b)    On March 20, 2024, Patrick Machado notified Chimerix, Inc. (the “Company”) of his resignation as a member of the Board of Directors (the “Board”) and as a member of all committees of the Board on which he serves, contingent upon and effective at the Company’s 2024 Annual Meeting of Stockholders, scheduled to be held on June 20, 2024. Mr. Machado’s decision to resign was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

(d)    On March 20, 2024, the Board appointed Marc Kozin, to serve as a Class III director of the Company, effective immediately.

In accordance with the Company’s non-employee director compensation policy, as amended, upon his appointment as a director, Mr. Kozin was granted a nonqualified stock option to purchase 100,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on the date of grant. One-third of the shares subject to the stock option will vest and become exercisable on the one-year anniversary of the date of grant and the balance of the shares will vest in a series of 24 equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the date of grant, subject to Mr. Kozin’s continuous service through each such vesting date and will vest in full upon a change in control. Additionally, Mr. Kozin will be entitled to receive a $40,000 annual retainer for his service as a director. At each annual stockholder meeting following which Mr. Kozin’s term as a director continues, he will be entitled to receive a nonqualified stock option to purchase 60,000 shares of the Company’s common stock, which will vest and become exercisable over a one-year period following the date of grant, subject to Mr. Kozin’s continuous service through each such vesting date and will vest in full upon a change in control. Mr. Kozin will also enter into the Company’s standard form of indemnification agreement for executive officers and directors. The Company is not aware of any transaction involving Mr. Kozin requiring disclosure under Item 404(a) of Regulation S-K.

Additional information about Mr. Kozin can be found in the press release issued by the Company, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No. Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 Chimerix, Inc.
Dated: March 21, 2024  
  By:/s/ Michelle LaSpaluto
  Michelle LaSpaluto
  Chief Financial Officer


Exhibit 99.1    
Chimerix Appoints Marc D. Kozin to Board of Directors

Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience

DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company’s 2024 Annual Meeting of Stockholders in June, after ten years of service.

“We are pleased to welcome Marc to the Board of Directors. Marc’s strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we work to advance our pipeline to commercialization,” said Mike Andriole, Chief Executive Officer of Chimerix. “We extend our gratitude to Pat for his exceptional service and unwavering dedication to Chimerix. His leadership and guidance have been instrumental in our achievements over the past decade. We wish him continued success in all his endeavors.”

Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management. Mr. Kozin previously served as President of L.E.K., a global strategy consulting firm, where he established the Boston office and led the development of the firm’s industry leading life science strategic planning practice. He currently serves on the Board of Directors of UFP Technologies (NASDAQ: UFPT) and HCRx Holdings.

Mr. Kozin holds a B.A. in Economics from Duke University and an M.B.A. from The Wharton School, University of Pennsylvania.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s continued growth and success and the advancement of its product pipeline. Among the factors and risks that could cause actual results to

Exhibit 99.1
differ materially from those indicated in the forward-looking statements are risks related to the timing, completion and outcome of the Phase 3 ACTION study of ONC201; risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies; risks related to the clinical development of ONC206; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

Will O’Connor
Stern Investor Relations